• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Contineum Therapeutics, Inc. - Common stock (NQ:CTNM)

9.310 +0.140 (+1.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Contineum Therapeutics, Inc. - Common stock

< Previous 1 2 Next >
News headline image
Contineum Therapeutics Announces Pricing of Upsized $90.0 Million Public Offering
December 11, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Proposed $75.0 Million Public Offering
December 11, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Attend the 8th Annual Evercore Healthcare Conference
November 24, 2025
From Contineum Therapeutics
Via Business Wire
News headline image
Contineum Therapeutics Reports Topline Data From Its Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
November 20, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Third-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
October 30, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Positive Topline Data From Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
September 18, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at September Investor Conferences
August 28, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Second-Quarter 2025 Financial Results; Updates Key Clinical Development Milestones
August 05, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Provides Update on Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
June 25, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2025 RBC Capital Markets Global Healthcare Conference
May 15, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports First-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones
May 14, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Appoints Timothy Watkins, M.D., M.Sc., as Chief Medical Officer and Head of Development
April 28, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Appointment of Diego Miralles, M.D. to Its Board of Directors
March 17, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the Stifel 2025 Virtual CNS Forum
March 12, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Fourth-Quarter 2024 Financial Results; Affirms Key Clinical Development Milestones
March 06, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Chronic Pain Trial of PIPE-791
March 04, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 2025 Leerink Partners Global Healthcare Conference
March 03, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Completes Enrollment in Phase 2 PIPE-307 VISTA Trial for the Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
January 08, 2025
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
RAPT Therapeutics Names Lori Lyons-Williams Chair of the Company’s Board of Directors
January 06, 2025
From RAPT Therapeutics, Inc.
Via GlobeNewswire
News headline image
Contineum Therapeutics Initiates Patient Dosing in Phase 1b Positron Emission Tomography (PET) Trial of PIPE-791
December 16, 2024
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Attend the 7th Annual Evercore HealthCONx Conference
November 25, 2024
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Expands Clinical Development of PIPE-791 With FDA Authorization of Its Investigational New Drug (IND) Application for Chronic Pain
November 18, 2024
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Attend Upcoming Investor Conferences
November 13, 2024
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights
November 06, 2024
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences
August 28, 2024
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
August 13, 2024
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Publication of Encouraging Data in the Proceedings of the National Academy of Sciences on PIPE-307, Its M1 Receptor Selective Inhibitor, in Clinical Development for Relapse-Remitting Multiple Sclerosis
July 31, 2024
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Appointment of Sarah Boyce to Board of Directors
June 24, 2024
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics to Present at the 45th Annual Goldman Sachs Healthcare Conference
June 04, 2024
From Contineum Therapeutics, Inc.
Via Business Wire
News headline image
Contineum Therapeutics Announces Appointment of John Healy as General Counsel & Corporate Secretary
June 03, 2024
From Contineum Therapeutics, Inc.
Via Business Wire
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap